Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Forxiga dapagliflozin Chronic kidney disease Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Forxiga Dapagliflozin Diabetes mellitus, type 2 List with clinical criteria and/or conditions Complete
Forxiga Dapagliflozin Diabetes mellitus, type 2 Do not list Complete
Forxiga dapagliflozin Heart failure with reduced ejection fraction Reimburse with clinical criteria and/or conditions Complete
Fosavance Alendronate sodium/cholecalciferol Osteoporosis Do not list Complete
Fosavance 70/5600 Alendronate sodium / cholecalciferol Osteoporosis List in a similar manner to other drugs in class Complete
Fosrenol Lanthanum carbonate hydrate Hyperphosphatemia, end-stage renal disease Do not list Complete
Fruzaqla fruquintinib Metastatic colorectal cancer (mCRC) Reimburse with clinical criteria and/or conditions Active
Fulphila pegfilgrastim Febrile neutropenia in non-myeloid malignancies N/A Complete
Fycompa Perampanel Epilepsy, partial onset seizures List with criteria/condition Complete